Related Experiment Video
Updated: Dec 13, 2025
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.6K
New Clue: Prediction from Cell-Free DNA
1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Journal of Clinical Medicine
|July 26, 2020
Summary
Early detection of chronic lung allograft dysfunction (CLAD) is crucial for lung transplant survival. Cell-free DNA (cfDNA) shows promise as a biomarker for monitoring CLAD progression and improving patient outcomes.
Area of Science:
- Biomarkers
- Transplantation immunology
- Genomics
Background:
- Chronic lung allograft dysfunction (CLAD) is a major obstacle to long-term lung transplant success.
- Early detection of CLAD is critical for timely intervention and improved patient prognosis.
- Cell-free DNA (cfDNA) is emerging as a potential non-invasive biomarker in various medical conditions.
Discussion:
- Joint assessment of cfDNA and CXCL10 in bronchoalveolar lavage (BAL) may help determine CLAD subphenotypes.
- This combined approach could potentially predict lung transplant survival rates.
- Further research is needed to validate cfDNA as a reliable biomarker for CLAD monitoring.
Key Insights:
- Cell-free DNA (cfDNA) holds potential for early detection of chronic lung allograft dysfunction (CLAD).
- Combining cfDNA with CXCL10 in bronchoalveolar lavage (BAL) may aid in CLAD subtyping and survival prediction.
- Accessible and reliable cfDNA biomarkers are needed to enhance lung transplant recipient monitoring.
Outlook:
- Development of cfDNA-based diagnostics could significantly improve long-term lung transplant outcomes.
- Continued research into cfDNA's role in allograft rejection is essential.
- Translating cfDNA findings into clinical practice will enhance patient management and survival.
